for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up
Healthcare

BRIEF-Maxcyte And Allogene Therapeutics Sign Clinical And Commercial License Agreement To Enable The Advancement Of Allogeneic Car T (Allocar T™) Therapies

March 24 (Reuters) - Allogene Therapeutics Inc:

* MAXCYTE AND ALLOGENE THERAPEUTICS SIGN CLINICAL AND COMMERCIAL LICENSE AGREEMENT TO ENABLE THE ADVANCEMENT OF ALLOGENEIC CAR T (ALLOCAR T™) THERAPIES

* ALLOGENE THERAPEUTICS - AGREEMENT ENABLES ALLOGENE TO UTILIZE MAXCYTE’S EXPERT PLATFORM IN TARGET CANDIDATES

* ALLOGENE THERAPEUTICS INC - UNDER TERMS, MAXCYTE TO GET UNDISCLOSED DEVELOPMENT, APPROVAL & COMMERCIAL MILESTONES IN ADDITION TO OTHER LICENSING FEES Source text for Eikon: Further company coverage:

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up